Fundraising Fox
XENA Dx
Techstars '23Ludwigshafen, DE · 1 known investors
Find your way into XENA Dx
Sign up to see every warm intro you have to XENA Dx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the XENA Dx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
XENA provides 3D surgical roadmaps generated from standard MRI scans to guide soft-tissue surgeries, particularly gynecological procedures like endometriosis, fibroids, and adenomyosis cases. The platform uses automated organ segmentation to create pre-operative 3D maps with disease visualization and intraoperative guidance displayed in the operating room.
Also known as Xena · XENA · Xena Dx
Founders & leadership
Investors · 1
How we know: the Techstars portfolio · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · Not right? Tell us
Company profile
researched Sep 2026XENA Dx is a German healthcare technology company developing a patient-specific surgical planning platform for complex gynecological surgery. The system converts a standard pelvic MRI into a 3D surgical map that shows disease extent, organ involvement and critical anatomy, with findings mapped against the bowel, bladder, ureters, uterus and ovaries and traceable back to the source images. The product, called XENA Atlas, is organized around four functions: mapping disease and organs, planning the approach and extent of excision, simulating the laparoscopic view from a chosen port of entry, and referencing the model, source MRI and saved planning views on an iPad in the operating room without additional hardware.
The workflow is designed around imaging the patient already has, described as protocol agnostic with 1 to 5 mm slices. MRI is transferred by PACS export, PowerShare or secure transfer; a model is built within one to two days, checked against the radiology read and reviewed by a practicing surgeon; the case is planned pre-operatively and the model is available on the day of surgery, with data de-identified and encrypted. The company also describes operative-video analysis that compares intraoperative footage against the preoperative model to document work beyond the standard procedure, which sites may use to support their preoperative record for coding purposes, with coding decisions remaining with the site.
The indication pipeline runs from endometriosis (described as in clinical validation) to adenomyosis and fibroids (clinical evaluation) and pelvic oncology (planned). The platform is described as investigational and not cleared for clinical use, with clinical evaluations underway with US programs and a 510(k) in preparation.
Founding story
Public sources identify Czuee Morey as CEO and founder and Deepali Godbole as co-founder and CTO. The company's site states that XENA began with Czuee's own experience of endometriosis. An earlier company description framed the work as building an AI-based, non-invasive detection solution for endometriosis, noting that diagnosis then typically required about seven years and a laparoscopic surgery for a condition affecting roughly 10% of women.
Business model
B2B software sold to hospitals and surgical programs. Caplight characterizes the customer profile as usage-based SaaS, subscription SaaS and services/consulting, with per-procedure billing among the descriptive keywords. The company's site frames commercial entry through a 10-case evaluation and demo requests, and points hospitals to reimbursement pathways including HCPCS C8001 for 3D anatomical segmentation for preoperative planning in the hospital outpatient setting, while noting that eligibility and payment depend on setting, payer and policy.
Software sold to hospitals, described by Caplight as usage-based and subscription SaaS alongside services and consulting, with per-procedure billing referenced among keywords. The company points to HCPCS C8001 for 3D anatomical segmentation for preoperative planning under HOPPS as a hospital outpatient payment pathway and notes that operative modifiers such as 22, 59/XS and 62/66 apply to the operation rather than to the model.
Traction
A prospective observational pilot of 20 consecutive laparoscopic surgeries for suspected or confirmed moderate-to-severe endometriosis reported that 43% of surgical plans were revised after model review, 91% concordance with operative findings and 60% improvement in surgeons' spatial understanding (Thott K, Godbole D, JMIG 2025). Clinical evaluations are described as underway with US programs. Caplight lists roughly five employees, total funding of $620,000, and monthly website visitors growing from 3.2K to 4.6K.
Latest developments
Caplight records a pre-seed round dated 2 September 2025, listed alongside a signal describing a $320K round from the State of Baden-Wurttemberg, and reports total funding of $620,000. In 2025 the company reported pilot results in a JMIG supplement abstract and states that clinical evaluations with US programs are underway with a 510(k) in preparation. Caplight also notes monthly website visitors growing 43% month over month from 3.2K to 4.6K.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
An early-stage, pre-seed medical AI company in surgical planning and medical imaging, tracked in European and secondary-market startup databases and listed by Caplight in the top 50% of tracked companies by its momentum index. Caplight identifies Surgiprint, XRlabs and Inzipio as the most similar companies. The company frames its market as gynecological surgery in the United States, citing 4 million surgeries annually.
The platform is positioned against the current practice of assembling surgical context from a written radiology report and 2D MRI slices reviewed one at a time, by presenting disease location, organ involvement, disease volume and at-risk structures in a single patient-specific 3D view that remains traceable to the source images. Additional differentiators claimed on the company's site include compatibility with existing MRI protocols at 1 to 5 mm slices, surgeon review of each model, iPad-based intraoperative reference requiring no extra hardware, a laparoscopic view simulation from the patient's own anatomy, and operative-video analysis linking the preoperative model to documented intraoperative work.
Technology
Automated 3D reconstruction and segmentation of pelvic MRI into patient-specific anatomical models covering organs, cavities, pathology, measurements and cross sections, with adjustable opacity, structure isolation and traceability of each mapped finding to the source image. The system supports laparoscopic view simulation with port selection, camera and uterine manipulator settings, and iPad-based access during surgery. A separate capability analyzes operative video against the preoperative model to confirm findings and document work beyond the standard procedure. Caplight categorizes the technology as application-layer medical AI spanning medical imaging, computer vision and precision medicine, including an anatomical foundation model.
Go-to-market
Direct engagement with hospitals and surgical programs, with the website offering a 10-case evaluation and demo requests as entry points and an ROI model for hospital buyers. Value arguments target surgical planning quality, earlier routing of complex cases to colorectal or urology support, staffing and room-time preparation, and a structured preoperative record of disease complexity. The model is also positioned for use in pre-consent conversations with patients. Participation in the Techstars accelerator provided network exposure.
Hospitals and surgical programs treating complex pelvic disease, including general gynecology, minimally invasive gynecologic surgery (MIGS) teams, and MIGS cases requiring colorectal or urology support; an earlier description also named clinicians, hospitals, insurers and patients as the target group.
Geography
Germany-based, with locations listed as Mannheim and Ludwigshafen (an earlier directory lists Munich). Clinical evaluations are described as underway with programs in the United States, and the reimbursement discussion references US hospital outpatient coding.
History
Directory listings give a founding year of 2022 (EU-Startups, Caplight), while the Techstars job board lists 2023. An accelerator round with Techstars is dated November 2023, followed by pre-seed rounds in August 2024 and September 2025, the latter associated with the State of Baden-Wurttemberg and L-Bank. Early positioning described an AI-based non-invasive detection approach for endometriosis; the current product is a preoperative and intraoperative 3D surgical planning platform with a clinical pilot published in 2025 and a 510(k) in preparation.
Risks & controversies
The product is explicitly investigational and not cleared for clinical use, with a 510(k) only in preparation, so US commercialization depends on regulatory clearance. Clinical evidence to date comes from a single prospective observational pilot of 20 consecutive cases reported in a conference supplement. Reimbursement is uncertain and setting-, payer- and policy-dependent, with coding responsibility resting with each site's compliance team; the company also notes that published disease-complexity data it cites are independent findings, not demonstrated XENA effects. Public records are inconsistent on founding year (2022 versus 2023) and headquarters (Mannheim, Ludwigshafen, Munich).
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsA prospective observational pilot across 20 consecutive laparoscopic surgeries for suspected or confirmed moderate-to-severe endometriosis reported 43% of surgical plans revised after model review, 91% concordance with operative findings and 60% improvement in surgeons' spatial understanding. Published as Thott K, Godbole D. JMIG. 2025;32(11 Suppl):S48.
The company states that clinical evaluations are underway with US programs, that the product is investigational and not yet cleared for clinical use, and that a 510(k) is in preparation.
Caplight lists an accelerator round dated 1 November 2023 with Techstars as investor; XENA Dx is listed on the Techstars job board as a pre-seed portfolio company.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- XENA Dxxenadx.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does XENA Dx do?
- German medical-AI startup turning pelvic MRI into patient-specific 3D surgical maps for complex gynecological surgery.
- Who are XENA Dx's investors?
- XENA Dx's investors include Techstars.
- Where is XENA Dx headquartered?
- XENA Dx is headquartered in Ludwigshafen, DE.